InsiderTrades.com logo
The Gold Grab of the Century
From Colonial Metals   |   Ad
When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.
That's why we have released our Free Precious Metals Investment Guide.
David M. Mott net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

David Mott Biography and Net Worth

Director of Epizyme
David M. Mott serves as Independent Chairman of the Board of the Company. Mr. Mott has served as a general partner of New Enterprise Associates, Inc., an investment firm focused on venture capital and growth equity investments and a holder of more than 5% of our voting securities, from September 2008 to February 2020, where he led the healthcare investing practice. From 1992 until 2008, Mr. Mott worked at MedImmune, Inc., or MedImmune, a biotechnology company and subsidiary of AstraZeneca Plc, or AstraZeneca, and served in numerous roles during his tenure, including most recently as Chief Executive Officer from October 2000 to July 2008. During that time, Mr. Mott also served as Executive Vice President of AstraZeneca from June 2007 to July 2008 following AstraZeneca’s acquisition of MedImmune in June 2007. Mr. Mott also serves as the Chairman of the board of directors of Ardelyx, Inc. and Adaptimmune and serves on the boards of several private biopharmaceutical companies. Mr. Mott received a B.A. from Dartmouth College.

What is David M. Mott's net worth?

The estimated net worth of David M. Mott is at least $171,128.58 as of March 25th, 2021. Mr. Mott owns 116,414 shares of Epizyme stock worth more than $171,129 as of April 26th. This net worth approximation does not reflect any other assets that Mr. Mott may own. Learn More about David M. Mott's net worth.

How do I contact David M. Mott?

The corporate mailing address for Mr. Mott and other Epizyme executives is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Epizyme can also be reached via phone at (617) 229-5872 and via email at [email protected]. Learn More on David M. Mott's contact information.

Has David M. Mott been buying or selling shares of Epizyme?

David M. Mott has not been actively trading shares of Epizyme during the past quarter. Most recently, on Thursday, March 25th, David M. Mott bought 28,231 shares of Epizyme stock. The stock was acquired at an average cost of $7.98 per share, with a total value of $225,283.38. Following the completion of the transaction, the director now directly owns 116,414 shares of the company's stock, valued at $928,983.72. Learn More on David M. Mott's trading history.

Who are Epizyme's active insiders?

Epizyme's insider roster includes Shefali Agarwal (Insider), Robert Bazemore Jr. (CEO), Joseph Beaulieu (Insider), Jeffery Kutok (Insider), Pablo Legorreta (Director), and David Mott (Director). Learn More on Epizyme's active insiders.

David M. Mott Insider Trading History at Epizyme

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/25/2021Buy28,231$7.98$225,283.38116,414View SEC Filing Icon  
6/26/2020Buy62,019$16.03$994,164.5782,601View SEC Filing Icon  
6/26/2019Sell104,944$13.08$1,372,667.5213,979View SEC Filing Icon  
10/5/2018Buy416,667$9.00$3,750,003.0012,088View SEC Filing Icon  
9/18/2017Buy200,000$15.25$3,050,000.006,000View SEC Filing Icon  
1/12/2016Buy1,111,111$9.00$9,999,999.00View SEC Filing Icon  
6/5/2013Buy400,000$15.00$6,000,000.00View SEC Filing Icon  
See Full Table

David M. Mott Buying and Selling Activity at Epizyme

This chart shows David M Mott's buying and selling at Epizyme by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Epizyme Company Overview

Epizyme logo
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.47
Low: $1.47
High: $1.47

50 Day Range

MA: $1.47
Low: $1.47
High: $1.52

2 Week Range

Now: $1.47
Low: $0.41
High: $5.80

Volume

7,960 shs

Average Volume

3,225,203 shs

Market Capitalization

$247.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
The Gold Grab of the Century
From Colonial Metals   |   Ad
When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.
That's why we have released our Free Precious Metals Investment Guide.